---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-012238"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:30:40.912685+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Pacira BioSciences reports Q4 2025 revenue of $196.9M, up 5%, and full-year 2026 guidance

## Summary
- Q4 2025 total revenue $196.9M (5% increase vs Q4 2024); EXPAREL sales $155.8M (+5%)
- Full-year 2025 revenue $726.4M; GAAP net income $7.0M vs net loss of $99.6M in 2024
- Repurchased 5.9M shares for $150.0M in 2025; $150M remaining authorization through Dec 2026
- 2026 guidance: EXPAREL net sales $600-620M, total revenue $745-770M, gross margin 77-79%
- Strategic partnership with LG Chem for EXPAREL in select Asian-Pacific markets; Samit Hirawat appointed to board

## SEC filing metadata
- accession: 0001628280-26-012238
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000162828026012238/0001628280-26-012238-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000162828026012238/pcrx-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-012238
- JSON: https://secwatch.observer/filing/0001628280-26-012238.json
- Plain text: https://secwatch.observer/filing/0001628280-26-012238.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.